What are the recent trends in market size and growth for the restless leg syndrome market?
The restless leg syndrome market size has grown rapidly in recent years. It will grow from $1.91 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to increasing rates of alcohol, increase in health insurance coverage, availability of over-the-counter medications, increasing public health initiatives and surge in mental health issues.
The restless leg syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.59 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increase in healthcare investment, awareness and education campaigns, increase in early diagnosis, increase in government funding, and enhanced clinical trial participation. Major trends in the forecast period include ai-powered personalized treatment plans, next-generation neurostimulation devices, deep learning algorithms for diagnosis, brainwave modulation technology, and wearable exoskeletons for leg movements.
Get Your Free Sample of The Global Restless Leg Syndrome Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21274&type=smp
How have varous drivers impacted the growth of the restless leg syndrome market?
The increasing prevalence of iron deficiency is expected to propel the growth of the restless leg syndrome market going forward. Iron deficiency refers to a condition in which the body lacks enough iron to produce sufficient healthy red blood cells, leading to symptoms such as fatigue, weakness, and pale skin. The increasing prevalence of iron deficiency is due to factors such as poor dietary intake, blood loss, malabsorption disorders, and increased iron requirements during pregnancy or growth. Restless leg syndrome treatment often involves iron supplementation or dietary adjustments, which not only help alleviate the uncomfortable urges and sensations but also work to correct underlying iron deficiency by replenishing iron stores in the body, improving red blood cell production, and restoring proper neurological function. For instance, in January 2025, according to the Nation Health Service England, an England-based government agency, in the 2023-24 period, there were 191,927 admissions due to iron deficiency, reflecting an 11% increase compared to 2022-23. Therefore, the increasing prevalence of iron deficiency drives the growth of the restless leg syndrome market.
What are the primary segments of the restless leg syndrome market?
The restless leg syndrome market covered in this report is segmented –
1) By Type: Primary Restless Legs Syndrome, Secondary Restless Legs Syndrome
2) By Treatment Type: Medicine And Devices, Surgery
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By Application: Neurological Treatment, Sleep Disorders, Movement Disorders, Symptom Management
Subsegments:
1) By Primary Restless Legs Syndrome: Idiopathic Restless Legs Syndrome, Hereditary Restless Legs Syndrome
2) By Secondary Restless Legs Syndrome: Iron Deficiency-related Restless Legs Syndrome, Chronic Kidney Disease-related Restless Legs Syndrome, Pregnancy-related Restless Legs Syndrome, Medication-induced Restless Legs Syndrome
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/restless-leg-syndrome-global-market-report
Which firms are leading the restless leg syndrome market?
Major companies operating in the restless leg syndrome market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Novartis International AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter International Inc., Astellas Pharma Inc., UCB S.A., Kyowa Kirin Co Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Mundipharma International Limited, Azurity Pharmaceuticals LLC, Otsuka Pharmaceutical Co Ltd., Horizon Therapeutics plc, Mylan N.V., Apollo Pharmacy Limited
How will industry trends affect the trajectory of the restless leg syndrome market?
Major companies operating in the restless leg syndrome (RLS) market are focused on developing innovative solutions, such as novel non-invasive therapies, to improve symptom management and enhance patient outcomes. Novel non-invasive therapies refer to innovative medical treatments that do not require surgery or penetration of the skin, aiming to provide relief from various conditions through advanced techniques such as electrical stimulation, light therapy, or external devices. For instance, in April 2023, Varco Leg Care, an India-based consumer health-technology company, received FDA De Novo approval for its NTX100 Tonic Motor Activation (TOMAC) System. The NTX100 Tonic Motor Activation (TOMAC) System is designed to treat moderate to severe symptoms of restless legs syndrome (RLS) and improve sleep quality in patients who do not respond to medications. The device works by electrically activating the peroneal nerves on both sides of the body to produce tonic, sustained muscle activation, which is compatible with sleep. This activation helps suppress the symptoms of restless leg syndrome (RLS).
Which geographic trends are shaping the restless leg syndrome market, and which region has the highest market share?
Europe was the largest region in the restless leg syndrome market in 2024. North-America is expected to be the fastest-growing region in the forecast period. The regions covered in the restless leg syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Restless Leg Syndrome Market Report 2025 Offer?
The restless leg syndrome market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Restless leg syndrome refers to a neurological condition characterized by an uncontrollable urge to move the legs, typically due to uncomfortable sensations. Treatment options include lifestyle changes, iron supplements, medications that affect dopamine levels, and strategies to improve sleep hygiene.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21274
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
